Reduced number of peripheral natural killer cells in schizophrenia but not in bipolar disorder

Brain, Behavior, and Immunity

Volumn 54, Issue , 2016, Pages 194-200

  Karpiński, Paweł ^a   Frydecka, Dorota ^a   Sasiadek, Maria M ^a   Misiak, Błazej ^a  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

Author keywords

Bipolar disorder; Computational deconvolution; Immunity; Inflammation; Lymphocytes; NK cells; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT; TRANSCRIPTOME;

ACUTE DISEASE; ADULT; ALGORITHM; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; DATA BASE; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MICROARRAY ANALYSIS; NATURAL KILLER CELL; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; RELAPSE; REMISSION; SCHIZOPHRENIA; BLOOD; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; IMMUNOLOGY; INFLAMMATION; MIDDLE AGED; PATHOLOGY;

ADULT; BIPOLAR DISORDER; CASE-CONTROL STUDIES; FEMALE; FLOW CYTOMETRY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFLAMMATION; KILLER CELLS, NATURAL; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; SCHIZOPHRENIA; TRANSCRIPTOME;

EID: 84958214356     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2016.02.005     Document Type: Article

References (67)

1. Abbas A.R., Wolslegel K., Seshasayee D., Modrusan Z., Clark H.F. Deconvolution of blood microarray data identifies cellular activation patterns in systemic lupus erythematosus. PLoS ONE 2009, 4:e6098.
2. Abeer, El-Sayed A., Ramy H.A. Immunological changes in patients with mania: changes in cell mediated immunity in a sample from Egyptian patients. Egypt. J. Immunol. 2006, 13:79-85.
3. Barbosa I.G., Rocha N.P., Assis F., Vieira E.L., Soares J.C., Bauer M.E., Teixeira A.L. Monocyte and lymphocyte activation in bipolar disorder: a new piece in the puzzle of immune dysfunction in mood disorders. Int. J. Neuropsychopharmacol. 2015, 18.
4. Barrett T., Wilhite S.E., Ledoux P., Evangelista C., Kim I.F., Tomashevsky M., Marshall K.A., Phillippy K.H., Sherman P.M., Holko M., Yefanov A., Lee H., Zhang N., Robertson C.L., Serova N., Davis S., Soboleva A. NCBI GEO: archive for functional genomics data sets - update. Nucleic Acids Res. 2013, 41:D991-D995.
5. Bilici M., Tekelioglu Y., Efendioglu S., Ovali E., Ulgen M. The influence of olanzapine on immune cells in patients with schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003, 27:483-485.
6. Brambilla P., Bellani M., Isola M., Bergami A., Marinelli V., Dusi N., Rambaldelli G., Tansella M., Finardi A.M., Martino G., Perlini C., Furlan R. Increased M1/decreased M2 signature and signs of Th1/Th2 shift in chronic patients with bipolar disorder, but not in those with schizophrenia. Transl. Psychiatry 2014, 4:e406.
7. Breunis M.N., Kupka R.W., Nolen W.A., Suppes T., Denicoff K.D., Leverich G.S., Post R.M., Drexhage H.A. High numbers of circulating activated T cells and raised levels of serum IL-2 receptor in bipolar disorder. Biol. Psychiatry 2003, 53:157-165.
8. Bukowska-Straková K., Baran J., Gawlicka M., Kowalczyk D. A false expression of CD8 antigens on CD4+ T cells in a routine flow cytometry analysis. Folia Histochem. Cytobiol. 2006, 44:179-183.
9. Clelland C.L., Read L.L., Panek L.J., Nadrich R.H., Bancroft C., Clelland J.D. Utilization of never-medicated bipolar disorder patients towards development and validation of a peripheral biomarker profile. PLoS ONE 2013, 8:e69082.
10. Dai M., Wang P., Boyd A.D., Kostov G., Athey B., Jones E.G., Bunney W.E., Myers R.M., Speed T.P., Akil H., Watson S.J., Meng F. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res. 2005, 33:e175.
11. Darcy C.J., Woodberry T., Davis J.S., Piera K.A., McNeil Y.R., Chen Y., Yeo T.W., Weinberg J.B., Anstey N.M. Increased plasma arginase activity in human sepsis: association with increased circulating neutrophils. Clin. Chem. Lab. Med. 2014, 52:573-581.
12. Davies G., Welham J., Chant D., Torrey E.F., McGrath J. A systematic review and meta-analysis of Northern Hemisphere season of birth studies in schizophrenia. Schizophr. Bull. 2003, 29:587-593.
13. de Pablo R., Monserrat J., Prieto A., Alvarez-Mon M. Role of circulating lymphocytes in patients with sepsis. Biomed. Res. Int. 2014, 2014:671087.
14. do Prado C.H., Rizzo L.B., Wieck A., Lopes R.P., Teixeira A.L., Grassi-Oliveira R., Bauer M.E. Reduced regulatory T cells are associated with higher levels of Th1/TH17 cytokines and activated MAPK in type 1 bipolar disorder. Psychoneuroendocrinology 2013, 38:667-676.
15. Drexhage R.C., Hoogenboezem T.H., Versnel M.A., Berghout A., Nolen W.A., Drexhage H.A. The activation of monocyte and T cell networks in patients with bipolar disorder. Brain Behav. Immun. 2011, 25:1206-1213.
16. Duale N., Lipkin W.I., Briese T., Aarem J., Rønningen K.S., Aas K.K., Magnus P., Harbak K., Susser E., Brunborg G. Long-term storage of blood RNA collected in RNA stabilizing Tempus tubes in a large biobank - evaluation of RNA quality and stability. BMC Res. Notes 2014, 7:633.
17. Fasold M., Binder H. Estimating RNA-quality using GeneChip microarrays. BMC Genomics 2012, 13:186.
18. Fasold M., Binder H. AffyRNADegradation: control and correction of RNA quality effects in GeneChip expression data. Bioinformatics 2013, 29:129-131.
19. Fineberg A.M., Ellman L.M. Inflammatory cytokines and neurological and neurocognitive alterations in the course of schizophrenia. Biol. Psychiatry 2013, 73:951-966.
20. Gaujoux R., Seoighe C. Cell Mix: a comprehensive toolbox for gene expression deconvolution. Bioinformatics 2013, 29:2211-2212.
21. Gautier L., Cope L., Bolstad B.M., Irizarry R.A. Affy - analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004, 20:307-315.
22. Guo J., Liu C., Wang Y., Feng B., Zhang X. Role of T helper lymphokines in the immune-inflammatory pathophysiology of schizophrenia: systematic review and meta-analysis. Nord. J. Psychiatry 2015, 69:364-372.
23. Harms R., Morsey B., Boyer C.W., Fox H.S., Sarvetnick N. Methamphetamine administration targets multiple immune subsets and induces phenotypic alterations suggestive of immunosuppression. PLoS ONE 2012, 7:e49897.
24. Jankowski M.M., Ignatowska-Jankowska B., Glac W., Swiergiel A.H. Cocaine administration increases CD4/CD8 lymphocyte ratio in peripheral blood despite lymphopenia and elevated corticosterone. Int. Immunopharmacol. 2010, 10:1229-1234.
25. Johnson W.E., Li C., Rabinovic A. Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics 2007, 8:118-127.
26. Kelley K.W., McCusker R.H. Getting nervous about immunity. Semin. Immunol. 2014, 26:389-393.
27. Khandaker G.M., Cousins L., Deakin J., Lennox B.R., Yolken R., Jones P.B. Inflammation and immunity in schizophrenia: implications for pathophysiology and treatment. Lancet Psychiatry 2015, 2:258-270.
28. Lauss M., Visne I., Kriegner A., Ringnér M., Jönsson G., Höglund M. Monitoring of technical variation in quantitative high-throughput datasets. Cancer Inform. 2013, 12:193-201.
29. Leboyer M., Soreca I., Scott J., Frye M., Henry C., Tamouza R., Kupfer D.J. Can bipolar disorder be viewed as a multi-system inflammatory disease?. J. Affect. Disord. 2012, 141:1-10.
30. Liwski C.J., Padley D.J., Gustafson M.P., Winters J.L., Gastineau D.A., Jacob E.K. Discordant CD34+ cell results in peripheral blood and hematopoietic progenitor cell-apheresis product: implications for clinical decisions and impact on patient treatment. Transfusion 2014, 54:541-544.
31. Maes M., Delange J., Ranjan R., Meltzer H.Y., Desnyder R., Cooremans W., Scharpe S. Acute phase proteins in schizophrenia, mania and major depression: modulation by psychotropic drugs. Psychiatry Res. 1997, 66:1-11.
32. Margari F., Petruzzelli M.G., Mianulli R., Campa M.G., Pastore A., Tampoia M. Circulating anti-brain autoantibodies in schizophrenia and mood disorders. Psychiatry Res. 2015, 230:704-708.
33. Mazzarello V., Cecchini A., Fenu G., Rassu M., Dessy L.A., Lorettu L., Montella A. Lymphocytes in schizophrenic patients under therapy: serological, morphological and cell subset findings. Ital. J. Anat. Embryol. 2004, 109:177-188.
34. McKenna F., McLaughlin P.J., Lewis B.J., Sibbring G.C., Cummerson J.A., Bowen-Jones D., Moots R.J. Dopamine receptor expression on human T- and B-lymphocytes, monocytes, neutrophils, eosinophils and NK cells: a flow cytometric study. J. Neuroimmunol. 2002, 132:34-40.
35. Mignini F., Streccioni V., Amenta F. Autonomic innervation of immune organs and neuroimmune modulation. Auton. Autacoid Pharmacol. 2003, 23:1-25.
36. Mihara T., Nakashima M., Kuroiwa A., Akitake Y., Ono K., Hosokawa M., Yamada T., Takahashi M. Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease. Parkinsonism Relat. Disord. 2008, 14:46-51.
37. Mikulak J., Bozzo L., Roberto A., Pontarini E., Tentorio P., Hudspeth K., Lugli E., Mavilio D. Dopamine inhibits the effector functions of activated NK cells via the upregulation of the D5 receptor. J. Immunol. 2014, 193:2792-2800.
38. Miller B.J., Buckley P., Seabolt W., Mellor A., Kirkpatrick B. Meta-analysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2011, 70:663-671.
39. Miller B.J., Gassama B., Sebastian D., Buckley P., Mellor A. Meta-analysis of lymphocytes in schizophrenia: clinical status and antipsychotic effects. Biol. Psychiatry 2013, 73:993-999.
40. Miller B.J., Kandhal P., Rapaport M.H., Mellor A., Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and cardiovascular risk in non-affective psychoses. Brain Behav. Immun. 2015, 45:28-35.
41. Miller J.A., Cai C., Langfelder P., Geschwind D.H., Kurian S.M., Salomon D.R., Horvath S. Strategies for aggregating gene expression data: the collapseRows R function. BMC Bioinformatics 2011, 12:322.
42. Munkholm K., Brauner J.V., Kessing L.V., Vinberg M. Cytokines in bipolar disorder vs. healthy control subjects: a systematic review and meta-analysis. J. Psychiatr. Res. 2013, 47:1119-1133.
43. Newman A.M., Liu C.L., Green M.R., Gentles A.J., Feng W., Xu Y., Hoang C.D., Diehn M., Alizadeh A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015, 12:453-457.
44. Nilsson H., Krawczyk K.M., Johansson M.E. High salt buffer improves integrity of RNA after fluorescence-activated cell sorting of intracellular labeled cells. J. Biotechnol. 2014, 192(Pt A):62-65.
45. Niwa F., Kuriyama N., Nakagawa M., Imanishi J. Effects of peripheral lymphocyte subpopulations and the clinical correlation with Parkinson's disease. Geriatr. Gerontol. Int. 2012, 12:102-107.
46. Poli A., Michel T., Thérésine M., Andrès E., Hentges F., Zimmer J. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology 2009, 126:458-465.
47. Pollak T.A., Beck K., Irani S.R., Howes O.D., David A.S., McGuire P.K. Autoantibodies to central nervous system neuronal surface antigens: psychiatric symptoms and psychopharmacological implications. Psychopharmacology 2015.
48. Rudolf S., Schlenke P., Broocks A., Peters M., Rothermundt M., Arolt V., Kirchner H. Search for atypical lymphocytes in schizophrenia. World J. Biol. Psychiatry 2004, 5:33-37.
49. Russell J.N., Clements J.E., Gama L. Quantitation of gene expression in formaldehyde-fixed and fluorescence-activated sorted cells. PLoS ONE 2013, 8:e73849.
50. Sasaki T., Nanko S., Fukuda R., Kawate T., Kunugi H., Kazamatsuri H. Changes of immunological functions after acute exacerbation in schizophrenia. Biol. Psychiatry 1994, 35:173-178.
51. Schattner A., Cori Y., Hahn T., Sirota P. No evidence for autoimmunity in schizophrenia. J. Autoimmun. 1996, 9:661-666.
52. Schwarz M.J., Chiang S., Muller N., Ackenheil M. T-helper-1 and T-helper-2 responses in psychiatric disorders. Brain Behav. Immun. 2001, 15:340-370.
53. Semiz M., Yildirim O., Canan F., Demir S., Hasbek E., Tuman T.C., Kayka N., Tosun M. Elevated neutrophil/lymphocyte ratio in patients with schizophrenia. Psychiatr. Danub. 2014, 26:220-225.
54. Severance E.G., Yolken R.H., Eaton W.W. Autoimmune diseases, gastrointestinal disorders and the microbiome in schizophrenia: more than a gut feeling. Schizophr. Res. 2014.
55. Shen-Orr S.S., Gaujoux R. Computational deconvolution: extracting cell type-specific information from heterogeneous samples. Curr. Opin. Immunol. 2013, 25:571-578.
56. Shen-Orr S.S., Tibshirani R., Khatri P., Bodian D.L., Staedtler F., Perry N.M., Hastie T., Sarwal M.M., Davis M.M., Butte A.J. Cell type-specific gene expression differences in complex tissues. Nat. Methods 2010, 7:287-289.
57. Sperner-Unterweger B., Whitworth A., Kemmler G., Hilbe W., Thaler J., Weiss G., Fleischhacker W.W. T-cell subsets in schizophrenia: a comparison between drug-naive first episode patients and chronic schizophrenic patients. Schizophr. Res. 1999, 38:61-70.
58. Steiner J., Jacobs R., Panteli B., Brauner M., Schiltz K., Bahn S., Herberth M., Westphal S., Gos T., Walter M., Bernstein H.G., Myint A.M., Bogerts B. Acute schizophrenia is accompanied by reduced T cell and increased B cell immunity. Eur. Arch. Psychiatry Clin. Neurosci. 2010, 260:509-518.
59. Subirana I., Sanz H., Vila J. Building bivariate tables: the compareGroups package for R. J. Stat. Softw. 2014.
60. Torres K.C., Souza B.R., Miranda D.M., Nicolato R., Neves F.S., Barros A.G., Dutra W.O., Gollob K.J., Correa H., Romano-Silva M.A. The leukocytes expressing DARPP-32 are reduced in patients with schizophrenia and bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33:214-219.
61. Werthén M., Sellborn A., Källtorp M., Elwing H., Thomsen P. In vitro study of monocyte viability during the initial adhesion to albumin- and fibrinogen-coated surfaces. Biomaterials 2001, 22:827-832.
62. Yadav V.K., De S. An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. Brief Bioinform. 2015, 16:232-241.
63. Yang Y., Wan C., Li H., Zhu H., La Y., Xi Z., Chen Y., Jiang L., Feng G., He L. Altered levels of acute phase proteins in the plasma of patients with schizophrenia. Anal. Chem. 2006, 78:3571-3576.
64. Yovel G., Sirota P., Mazeh D., Shakhar G., Rosenne E., Ben-Eliyahu S. Higher natural killer cell activity in schizophrenic patients: the impact of serum factors, medication, and smoking. Brain Behav. Immun. 2000, 14:153-169.
65. Zhao W., Huang Y., Liu Z., Cao B.B., Peng Y.P., Qiu Y.H. Dopamine receptors modulate cytotoxicity of natural killer cells via cAMP-PKA-CREB signaling pathway. PLoS ONE 2013, 8:e65860.
66. Zhong Y., Wan Y.W., Pang K., Chow L.M., Liu Z. Digital sorting of complex tissues for cell type-specific gene expression profiles. BMC Bioinformatics 2013, 14:89.
67. Ziemssen T., Kern S. Psychoneuroimmunology-cross-talk between the immune and nervous systems. J. Neurol. 2007, 254(Suppl. 2):II8-II11.